Revvity: Can It Reignite Growth With New Product Launches & Strategic Partnerships?

Revvity’s third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned with expectations despite unfavorable forex fluctuations. The company’s Signals software division proved a strong performer, with 20% organic growth, and their reproductive health segment also showed notable progress. However, the Diagnostic segment experienced a significant decline in China due to lingering DRG impacts, though the non-China segment performed robustly, growing in the high single digits. From a financial perspective, Revvity achieved a 26.1% adjusted operating margin, marginally surpassing expectations, and reported adjusted earnings per share of $1.18, a $0.05 improvement over forecasted figures. The firm exhibited efficient capital deployment, with a robust focus on cash flow resulting in a 90% conversion of adjusted net income into free cash flow. The company also actively engaged in share repurchases, expending $205 million to buy back 2.